Login to Your Account



Doctors' Economics Matter

Some Drugs Sell Themselves; Others Don't, Spectrum Finds

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, December 19, 2011

Despite a better efficacy and safety profile than Rituxan (rituximab, Roche AG and Biogen Idec Inc.), Zevalin ([90Y]-ibritumomab tiuxetan), the radioactive form of Rituxan, has never been a big seller.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription